Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrence of VTE ( · people with distal DVT
Anticoagulant leads to lower recurrence of VTE ( compared with no intervention or placebo (high certainty).
1 finding from 1 review
Major bleeding · people with distal DVT
Anticoagulant showed no clear difference in major bleeding ( compared with no intervention or placebo (low certainty).
1 finding from 1 review
Recurrence of DVT ( · people with distal DVT
Anticoagulant leads to lower recurrence of DVT ( compared with no intervention or placebo (high certainty).
1 finding from 1 review
PE ( · people with distal DVT
Anticoagulant showed no clear difference in PE ( compared with no intervention or placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people with distal DVT
Anticoagulant leads to higher clinically relevant non‐major bleeding ( compared with no intervention or placebo (high certainty).
1 finding from 1 review
Overall mortality ( · people with distal DVT
Anticoagulant showed no clear difference in overall mortality ( compared with no intervention or placebo (low certainty).
1 finding from 1 review
Mortality related to PE ( · people with distal DVT
1 finding from 1 review
Thrombosis · people with antiphospholipid antibodies and no history of thrombosis
Anticoagulant with or without ASA showed no clear difference in thrombosis Median compared with ASA only (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Minor bleeding · people with antiphospholipid antibodies and no history of thrombosis
Anticoagulant with or without ASA may leads to higher bleeding ‐ minor (not requiring hospital admission) Median compared with ASA only (low certainty).
1 finding from 1 review
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
Anticoagulant with or without ASA led to lower adverse event other than bleeding compared with ASA only; GRADE not reported.
1 finding from 1 review
no estimate extracted
2014 participants
GRADE not reported
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found